These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1010 related items for PubMed ID: 16812979

  • 1. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 4. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 5. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec 29; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 7. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 8. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP, Maggioni A, Velazquez EJ.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun 15; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [Abstract] [Full Text] [Related]

  • 9. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA.
    Circulation; 2005 Jun 28; 111(25):3411-9. PubMed ID: 15967846
    [Abstract] [Full Text] [Related]

  • 10. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM.
    Clin Sci (Lond); 2012 Dec 28; 123(11):649-58. PubMed ID: 22715807
    [Abstract] [Full Text] [Related]

  • 11. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.
    Ital Heart J; 2005 Nov 28; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [Abstract] [Full Text] [Related]

  • 12. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group).
    Savoye C, Equine O, Tricot O, Nugue O, Segrestin B, Sautière K, Elkohen M, Pretorian EM, Taghipour K, Philias A, Aumégeat V, Decoulx E, Ennezat PV, Bauters C, REmodelage VEntriculaire study group.
    Am J Cardiol; 2006 Nov 01; 98(9):1144-9. PubMed ID: 17056315
    [Abstract] [Full Text] [Related]

  • 13. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Nov 01; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 14. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 01; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 15. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
    Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD, VALsartan In Acute myocardial iNfarcTion (VALIANT) Trial Investigators.
    Am Heart J; 2010 Jul 01; 160(1):145-51. PubMed ID: 20598985
    [Abstract] [Full Text] [Related]

  • 16. Late ventricular remodeling in non-reperfused acute myocardial infarction in humans is predicted by angiotensin II type 1 receptor density on blood platelets.
    Maczewski M, Borys M, Kacprzak P, Gdowski T, Kowalewski M, Wojciechowski D.
    Int J Cardiol; 2008 Jun 23; 127(1):57-63. PubMed ID: 17651844
    [Abstract] [Full Text] [Related]

  • 17. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
    Prisant LM.
    Am J Med; 2008 Aug 23; 121(8 Suppl):S8-15. PubMed ID: 18638617
    [Abstract] [Full Text] [Related]

  • 18. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.
    Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA, Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators.
    Eur Heart J; 2011 May 23; 32(10):1227-34. PubMed ID: 21317148
    [Abstract] [Full Text] [Related]

  • 19. [Effect of ACE-inhibitors on left ventricular remodeling after acute anterior or posterior myocardial infarct. Cine- magnetic resonance tomography study].
    Konermann M, Odenthal HJ, Altmann C, Laschewski F, Rawert B, Trappe HJ, Sanner BM.
    Wien Med Wochenschr; 2000 May 23; 150(12):249-55. PubMed ID: 11008329
    [Abstract] [Full Text] [Related]

  • 20. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA.
    Circulation; 2004 Sep 21; 110(12):1572-8. PubMed ID: 15364810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.